Aequus Pharmaceuticals Stock Today
| AQS Stock | CAD 0.01 0.01 100.00% |
Performance7 of 100
| Odds Of DistressOver 58
|
Aequus Pharmaceuticals is selling for under 0.01 as of the 28th of November 2024; that is 100.00 percent increase since the beginning of the trading day. The stock's lowest day price was 0.01. Aequus Pharmaceuticals has over 58 % chance of experiencing financial distress in the next 2 years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Aequus Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. Aequus Pharmaceuticals Inc. was founded in 2013 and is headquartered in Vancouver, Canada. AEQUUS PHARMACEUTICALS operates under Drug Manufacturers - Specialty Generic classification in Canada and is traded on TSX Venture Exchange. The company has 132.63 M outstanding shares of which 625 shares are presently shorted by private and institutional investors with about 0.02 days to cover all short positions. More on Aequus Pharmaceuticals
Moving against Aequus Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Aequus Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Aequus Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Aequus Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman | Douglas Janzen | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Pharmaceuticals, Drug Manufacturers - Specialty & Generic, Healthcare (View all Sectors) | ||||
Aequus Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Aequus Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsAequus Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Aequus Pharmaceuticals' financial leverage. It provides some insight into what part of Aequus Pharmaceuticals' total assets is financed by creditors.
| |||||
Aequus Pharmaceuticals (AQS) is traded on TSX Venture Exchange in Canada and employs 6 people. Aequus Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.33 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Aequus Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Aequus Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Aequus Pharmaceuticals classifies itself under Pharmaceuticals sector and is part of Health Care industry. The entity has 132.63 M outstanding shares of which 625 shares are presently shorted by private and institutional investors with about 0.02 days to cover all short positions.
Aequus Pharmaceuticals has accumulated about 1.46 M in cash with (2.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Aequus Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationAequus Pharmaceuticals holds a total of 132.63 Million outstanding shares. Aequus Pharmaceuticals shows 14.68 percent of its outstanding shares held by insiders and 0.0 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Aequus Ownership Details
Aequus Pharmaceuticals Risk Profiles
Although Aequus Pharmaceuticals' alpha and beta are two of the key measurements used to evaluate Aequus Pharmaceuticals' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 13.81 | |||
| Semi Deviation | 15.55 | |||
| Standard Deviation | 26.79 | |||
| Variance | 717.88 |
Aequus Stock Against Markets
| AQS | 100.00 |
| Competition | Compare Correlations |
Be your own money manager
Our tools can tell you how much better you can do entering a position in Aequus Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Price Ceiling Movement Now
Price Ceiling MovementCalculate and plot Price Ceiling Movement for different equity instruments |
| All Next | Launch Module |
Aequus Pharmaceuticals Corporate Management
Elected by the shareholders, the Aequus Pharmaceuticals' board of directors comprises two types of representatives: Aequus Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aequus. The board's role is to monitor Aequus Pharmaceuticals' management team and ensure that shareholders' interests are well served. Aequus Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aequus Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rabin Ramanjoolo | Chief Officer | Profile | |
| Grant Larsen | Chief Officer | Profile | |
| Rabin Ramanjooloo | Chief Officer | Profile | |
| Stuart Fowler | Strategic Director | Profile |
Additional Tools for Aequus Stock Analysis
When running Aequus Pharmaceuticals' price analysis, check to measure Aequus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aequus Pharmaceuticals is operating at the current time. Most of Aequus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aequus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aequus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aequus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.